This study evaluated the effectiveness of bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with non-platinum chemotherapy for patients with recurrent, persistent, or metastatic cervical cancer. The trial, conducted by the Gynecologic Oncology Group (GOG) and the Spanish Research Group for Ovarian Cancer, involved 452 patients randomly assigned to receive either cisplatin-paclitaxel chemotherapy alone or in combination with bevacizumab. The primary endpoint was overall survival, with a reduction of 30% in the hazard ratio for death considered clinically important. The results showed that the addition of bevacizumab to chemotherapy significantly improved median overall survival (17.0 months vs. 13.3 months) and response rates (48% vs. 36%). However, bevacizumab was associated with an increased incidence of hypertension, thromboembolic events, and gastrointestinal fistulas. The study concluded that the addition of bevacizumab to combination chemotherapy in advanced cervical cancer improved median overall survival by 3.7 months, making it a valuable treatment option for patients with this disease.This study evaluated the effectiveness of bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with non-platinum chemotherapy for patients with recurrent, persistent, or metastatic cervical cancer. The trial, conducted by the Gynecologic Oncology Group (GOG) and the Spanish Research Group for Ovarian Cancer, involved 452 patients randomly assigned to receive either cisplatin-paclitaxel chemotherapy alone or in combination with bevacizumab. The primary endpoint was overall survival, with a reduction of 30% in the hazard ratio for death considered clinically important. The results showed that the addition of bevacizumab to chemotherapy significantly improved median overall survival (17.0 months vs. 13.3 months) and response rates (48% vs. 36%). However, bevacizumab was associated with an increased incidence of hypertension, thromboembolic events, and gastrointestinal fistulas. The study concluded that the addition of bevacizumab to combination chemotherapy in advanced cervical cancer improved median overall survival by 3.7 months, making it a valuable treatment option for patients with this disease.